此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Symbiotic-Lung-14:一项关于研究药物PF08634404联合化疗用于成人转化性小细胞肺癌患者的研究

2026年10月6日 更新者:Pfizer

一项针对既往未治疗的转化性小细胞肺癌受试者中PF-08634404联合化疗的2期干预性研究

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.

To join the study, participants must meet the following conditions:

  • Are aged 18 years or older
  • Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)
  • Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)
  • Have healthy organs based on medical tests and are in good physical condition

After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100730
        • 招聘中
        • Peking Union Medical College Hospital
    • Fujian
      • Fuzhou、Fujian、中国、350014
        • 招聘中
        • Fujian Cancer Hospital
    • Henan
      • Zhengzhou、Henan、中国、450008
        • 招聘中
        • Henan Cancer Hospital
    • Hubei
      • Wuhan、Hubei、中国、430048
        • 招聘中
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    • Jiangxi
      • Nanchang、Jiangxi、中国、330200
        • 招聘中
        • The First Affiliated Hospital of Nanchang University
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200030
        • 招聘中
        • Shanghai Chest Hospital
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310003
        • 招聘中
        • The first Affiliated Hospital, Zhejiang University School of Medicine
    • HA Merkaz
      • Ramat Gan、HA Merkaz、以色列、5265601
        • 招聘中
        • Sheba Medical Center
    • Jerusalem
      • Jerusalem、Jerusalem、以色列、9103102
        • 招聘中
        • Shaare Zedek Medical Center
    • Kerala
      • Kottayam、Kerala、印度、686630
        • 招聘中
        • Caritas Hospital and Institute of Health Sciences
    • National Capital Territory of Delhi
      • New Delhi、National Capital Territory of Delhi、印度、110085
        • 招聘中
        • Rajiv Gandhi Cancer Institute And Research Centre
      • Tainan、台湾、704302
        • 招聘中
        • National Cheng Kung University Hospital
      • Taipei、台湾、100
        • 招聘中
        • National Taiwan University Hospital
      • Taipei、台湾、11217
        • 招聘中
        • Taipei Veterans General Hospital
      • Taipei、台湾、106
        • 招聘中
        • National Taiwan University Cancer Center (NTUCC)
      • Porto Alegre、巴西、90610-000
        • 招聘中
        • Hospital São Lucas da PUCRS
      • São Paulo、巴西、01452-000
        • 尚未招聘
        • Centro Paulista de Oncologia Clínica
    • São Paulo
      • São Paulo、São Paulo、巴西、01321-001
        • 招聘中
        • Hospital Beneficência Portuguesa de São Paulo
      • Bergamo、意大利、24125
        • 招聘中
        • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni
    • ROME
      • Roma、ROME、意大利、00144
        • 尚未招聘
        • IRCCS Istituto Nazionale dei Tumori Regina Elena
    • Turin
      • Orbassano、Turin、意大利、10043
        • 招聘中
        • A.O.U. San Luigi Gonzaga
      • Osaka、日本、541-8567
        • 招聘中
        • Osaka International Cancer Institute(OICI)
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、464-8681
        • 招聘中
        • Aichi Cancer Center Hospital
    • Okayama-ken
      • Kita、Okayama-ken、日本、700-8558
        • 尚未招聘
        • Okayama University Hospital
    • Osaka
      • Hirakata、Osaka、日本、573-1191
        • 招聘中
        • Kansai Medical University Hospital
    • Tokyo
      • Chūō、Tokyo、日本、104-0045
        • 招聘中
        • National Cancer Center - Tsukiji Campus
      • Kotoku、Tokyo、日本、135-8550
        • 招聘中
        • Japanese Foundation for Cancer Research
      • Lyon、法国、69373
        • 招聘中
        • Centre Léon Bérard
      • Marseille、法国、13915
        • 招聘中
        • Assistance Publique Hôpitaux de Marseille - Hôpital Nord
      • Villejuif、法国、94805
        • 尚未招聘
        • Institut Gustave Roussy
    • New South Wales
      • Westmead、New South Wales、澳大利亚、2145
        • 尚未招聘
        • Westmead Hospital
    • South Australia
      • Elizabeth Vale、South Australia、澳大利亚、5112
        • 招聘中
        • Calvary Connery Centre
    • Victoria
      • Heidelberg、Victoria、澳大利亚、3084
        • 尚未招聘
        • Warringal Private Hospital
    • California
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope National Medical Center
      • Encinitas、California、美国、92024
        • 招聘中
        • UC San Diego Medical Center - Encinitas
      • Irvine、California、美国、92618
        • 招聘中
        • City of Hope Lennar Foundation Cancer Center
      • La Jolla、California、美国、92037
        • 招聘中
        • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
      • La Jolla、California、美国、92037
        • 招聘中
        • UC San Diego Sulpizio Cardiovascular Center
      • La Jolla、California、美国、92037
        • 招聘中
        • UC San Diego Moores Cancer Center
      • La Jolla、California、美国、92037
        • 招聘中
        • UC San Diego Koman Family Outpatient Pavilion
      • San Diego、California、美国、92101
        • 招聘中
        • UC San Diego Medical Center - Bankers Hill
      • San Diego、California、美国、92103
        • 招聘中
        • UC San Diego McGrath Outpatient Pavilion - Hillcrest
      • San Diego、California、美国、92127
        • 招聘中
        • UC San Diego Medical Center - Rancho Bernardo
      • San Diego、California、美国、92103
        • 招聘中
        • UC San Diego Medical Center- Hillcrest
      • Vista、California、美国、92081
        • 招聘中
        • UC San Diego Medical Center - Vista
    • Illinois
      • Hinsdale、Illinois、美国、60521
        • 招聘中
        • Hope and Healing Clinical Research
      • New Lenox、Illinois、美国、60451
        • 招聘中
        • Hope and Healing Clinical Research
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • MSK Basking Ridge
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • MSK Monmouth
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • MSK Bergen.
    • New York
      • Commack、New York、美国、11725
        • 招聘中
        • MSK Commack
      • Harrison、New York、美国、10604
        • 招聘中
        • MSK Westchester
      • Long Island City、New York、美国、11101
        • 招聘中
        • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
      • New York、New York、美国、10021
        • 招聘中
        • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
      • Uniondale、New York、美国、11553
        • 招聘中
        • MSK Nassau
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre
      • Seville、西班牙、41013
        • 招聘中
        • Hospital Universitario Virgen Del Rocio
    • Catalunya [cataluña]
      • L'Hospitalet de Llobregat、Catalunya [cataluña]、西班牙、08908
        • 招聘中
        • Institut Català d'Oncologia - L'Hospitalet
      • Hong Kong、香港
        • 招聘中
        • Queen Mary Hospital
      • Hong Kong、香港
        • 招聘中
        • Prince of Wales Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female participants aged ≥18 years at the time of informed consent.
  • Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
  • Participants have not received systemic therapy for T-SCLC.
  • Have at least one measurable lesion as the target lesion based on RECIST v1.1.
  • Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Have a minimum life expectancy of >12 weeks.
  • Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter <1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.

  • Leptomeningeal disease

  • Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula

  • History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)

  • Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)

  • History of allogeneic organ or hematopoietic stem cell transplantation

  • Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)

  • Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:

    • Prior or current non-infectious pneumonitis requiring systemic therapy
    • DLCO <50% predicted
    • Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
  • Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose

  • Baseline QTcF >480 msec

  • Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study

  • Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage

  • History of significant bleeding disorders or recent major bleeding events

  • Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding

  • Active, uncontrolled, or symptomatic infection, including:

    • Active TB
    • Active hepatitis B or C
    • Uncontrolled HIV infection
  • History of immunodeficiency

  • Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies

  • Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation

  • Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods

  • Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes

  • Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)

  • Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PF-08634404

Participants will receive PF-08634404 in combination with chemotherapy intravenously, followed by maintenance therapy with PF-08634404.

Injection for intravenous use

Concentrate for solution for infusion

其他名称:
  • SSGJ-707

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
大体时间:From start of treatment until first documented CR or PR (approximately maximum up to 1 years)

Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator.

From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
Number of Participants with Adverse Events (AEs)
大体时间:Up to 90 days after the last dose of treatment

Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Up to 90 days after the last dose of treatment

次要结果测量

结果测量
措施说明
大体时间
PF-08634404抗药抗体的发生率
大体时间:末次治疗给药后最多37天
末次治疗给药后最多37天
药代动力学:PF-08634404给药前和给药后血清浓度
大体时间:最后一次治疗剂量后最多37天
最后一次治疗剂量后最多37天
Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1
大体时间:Up to approximately 2 years after completion of study treatment of last study participant

PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first

Up to approximately 2 years after completion of study treatment of last study participant
Number of participants with Laboratory abnormalities
大体时间:Up to 90 days after the last dose of treatment

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

Up to 90 days after the last dose of treatment
Duration of Response (DOR) as assessed by investigator based on RECIST v1.1
大体时间:Up to approximately 2 years after completion of study treatment of last study participant

DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of disease progression (PD) or death due to any cause.

Up to approximately 2 years after completion of study treatment of last study participant
Overall Survival (OS)
大体时间:Up to approximately 2 years after completion of study treatment of last study participant

OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study.

Up to approximately 2 years after completion of study treatment of last study participant

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月2日

初级完成 (估计的)

2028年3月24日

研究完成 (估计的)

2031年3月24日

研究注册日期

首次提交

2026年3月13日

首先提交符合 QC 标准的

2026年3月13日

首次发布 (实际的)

2026年3月17日

研究记录更新

最后更新发布 (实际的)

2026年10月9日

上次提交的符合 QC 标准的更新

2026年10月6日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • C6461014
  • 2025-524686-24-00 (注册表标识符:CTIS (EU))
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅